1. Where we were on December 31: a niche oncology platform with a long runway

On December 31, 2025, when we published the original Merlintrader article on Alpha Tau Medical, DRTS was still a quiet name on most biotech screens. The stock had just closed the year at roughly $4.95 per share, after spending much of 2025 oscillating in a wide range between about $2.30 and $5.00. Market cap sat in the mid-hundreds of millions of dollars, and the story was mostly followed by a tight group of specialists focused on novel radiation platforms rather than by the broader retail crowd.

The core of the thesis was simple: Alpha Tau is trying to turn Alpha DaRT into a multi-indication platform technology for solid tumors. By implanting intratumoral sources that emit short-range alpha particles, the company aims to deliver highly localized, intense radiation that destroys the tumor while sparing surrounding healthy tissue. The original deep dive focused on the idea that, if the technology works across several tumors, the company is not “just” a single-indication bet but a portfolio of oncology options embedded into one platform.

From a balance-sheet perspective, we highlighted the Q3 2025 financial update , which showed approximately $75.9 million in cash, cash equivalents, short-term deposits and restricted deposits as of September 30, 2025. That figure, combined with the company’s operating profile, translated into a comfortable multi-year runway to continue advancing the pipeline and preparing manufacturing without any immediate balance-sheet stress.

In other words, by late December the setup was: a differentiated radiation platform, several clinical programs progressing in parallel, a newly licensed manufacturing facility in New Hampshire, and enough cash to actually run the plan. What was still missing was visibility. That changed fast in January.

2. January 2026: DRTS moves from quiet corner to crowded trade

The simplest way to understand what happened next is to look at the tape. Between December 31, 2025 and the end of January 2026, DRTS staged a remarkable repricing:

Daily volume expanded meaningfully relative to the low-liquidity days of mid-2025, and DRTS started to appear more frequently on momentum and “unusual volume” lists. On Reddit and Stocktwits, the dedicated DRTS communities and Alpha Tau threads moved from a handful of comments a week to multi-thread discussions dissecting every data point and trading swing.

A key point in this transition is that the move was not purely technical. The tape was reacting to real, incremental information: formal progress toward U.S. regulatory filing for cutaneous squamous cell carcinoma (cSCC), new pancreatic cancer data presented at ASCO GI, and a shareholder letter that pulled together the story across five concurrent U.S. trials. The rally is not proof that the story will ultimately succeed, but it is evidence that the market is starting to treat Alpha Tau as a serious platform contender rather than an obscure micro-cap.

3. January newsflow: PMA module, pancreatic data and a shareholder letter that changed the narrative

3.1 First PMA module submitted for cSCC (ReSTART trial)

On January 5, 2026, Alpha Tau announced that it had submitted the first module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration for the use of Alpha DaRT in recurrent cutaneous squamous cell carcinoma (r-cSCC) of the skin and head and neck region, based on its ongoing pivotal ReSTART trial in the United States. The company described this as a staged or modular PMA process, where components of the full dossier are submitted and reviewed in sequence. The move is important for two reasons: it crystallizes cSCC as the “lead” commercial indication, and it confirms that Alpha Tau and the FDA are aligned enough on the trial and manufacturing package to start the regulatory machinery.

In the same communication, management reiterated that patient enrollment in ReSTART is expected to be completed around Q1 2026, bringing the key inflection point for r-cSCC much closer in time than most retail investors had appreciated during 2025. For a platform name, having a relatively near-term pivotal readout in a visibly disfiguring skin cancer is a powerful anchor for the story.

3.2 New pancreatic cancer data at ASCO GI 2026 (Montreal)

On January 6, 2026, Alpha Tau followed with another press release previewing new data that would be presented at ASCO GI 2026 in Montreal on the use of Alpha DaRT in pancreatic cancer. In the pilot study, patients received Alpha DaRT on top of modern chemotherapy, and the early data showed encouraging signals: disease control rates in the eighty-percent range and objective responses in a setting where historical expectations are grim. The company also highlighted immune-related observations, such as changes in inflammatory markers that could hint at systemic effects beyond the local tumor.

The market’s reaction was straightforward: the combination of cSCC as the front-line commercial opportunity and pancreatic cancer as a high-unmet-need expansion path created an upgraded mental model. Instead of thinking of Alpha DaRT as a niche skin-only solution, investors started to price in the option value of a platform that could move from skin to deep visceral tumors over time.

3.3 Shareholder letter: five concurrent U.S. trials and a clearer roadmap

Toward the end of January, Alpha Tau released a shareholder letter summarizing where the company stands after the Q3 results and the early-2026 clinical progress. The letter reinforced a few key messages:

• Five concurrent U.S. trials across r-cSCC, pancreatic, glioblastoma and other indications.
• Operational progress at the New Hampshire manufacturing facility, licensed for radioactive material.
• Targeted milestones in 2026: completion of ReSTART enrollment, more pancreatic data, Japan PMDA response, GBM starts.

Importantly, the letter helped retail investors and smaller funds to see the structure of the story. Instead of a collection of press releases, there is now a more coherent roadmap: establish Alpha DaRT in r-cSCC as the lead commercial foothold, keep adding indications on top through a mix of company-sponsored and investigator-initiated trials, and build manufacturing capacity that can actually support real-world demand if approvals arrive.

4. Fundamentals refresh: cash, operating profile and runway

All the enthusiasm around the data and regulatory traction would matter much less if the company were forced to constantly look over its shoulder at near-term financing stress. That is not the case here, based on the most recent official financials.

In the Q3 2025 financial results , Alpha Tau reported:

The key takeaway is that Alpha Tau entered the 2026 catalyst window with a balance sheet that allows it to pursue its clinical and operational plan at a reasonable pace. There is no sense in the official filings of an urgent need to radically change the cost structure or slow down clinical activity just to survive the next few quarters. That is precisely the kind of runway that gives a complex, multi-trial program a real chance to mature.

5. Analyst coverage and targets: still catching up with the story

The sell-side coverage on DRTS is still relatively light compared with more established oncologic names, but it has started to reflect the shift from “interesting science” to “potentially near-term commercial story”. Recent data from major financial portals that aggregate analyst estimates show a small group of firms covering Alpha Tau with a broadly constructive stance: consensus ratings cluster in the “Buy/Outperform” area, with no formal “Sell” ratings reported at the time of writing.

On the target side, public consensus data indicate an average price target in the mid-single digits to low-double digits per share, with the lowest targets around the current trading range and the highest stretching toward the low-teens. That implies upside potential from current levels in most published scenarios, though obviously those targets are dynamic and can move both up and down as data mature.

What matters more than the exact number is the message: after the PMA module and the ASCO GI pancreatic update, analysts are increasingly forced to treat DRTS not as a binary “will Alpha DaRT work?” question but as a spectrum of possibilities across multiple indications: cSCC as a core, head and neck as a key follow-on, pancreatic and GBM as high-risk, high-reward expansions. That kind of structure usually supports more nuanced research and, over time, better-informed institutional positioning.

6. Retail sentiment: from obscure ticker to “alpha radiation” cult stock

If you scroll back to mid-2025 threads on r/biotechstocks or generic biotech Discords, Alpha Tau barely shows up. A couple of posts, some mentions of “interesting alpha radiation tech”, and not much more. By late January 2026, the picture is very different.

Dedicated communities such as the DRTS subreddit and Alpha Tau-focused boards now host long threads dissecting:

• The probability of success of the ReSTART pivotal trial in r-cSCC.
• What pancreatic data at ASCO GI really mean versus standard of care.
• The potential role of the New Hampshire facility if approvals arrive.
• The risk that competition or regulators slow down the story.

On Stocktwits, the number of watchers and daily messages has increased significantly versus 2025. The tone is what you would expect from a small-mid cap with an exciting platform and a strong chart: a mix of long-term believers who have been following Alpha Tau since before the U.S. listing, newer traders attracted by the recent breakout, and skeptics pointing out the usual pitfalls of oncology development.

The interesting part is how often long-form official materials are now referenced in those retail discussions. The company’s site, the Q3 financial release, and the January press releases are quoted directly and linked in comment threads. That is usually a sign that a ticker has graduated from pure speculation to a more serious, due-diligence-driven following, even if the day-to-day trading can still be volatile and emotional.

Sentiment note: Reddit, Stocktwits and X are populated mainly by non-professional traders and investors. The tone of the debate can be noisy, emotional and heavily biased by short-term price moves. These channels are useful to feel how the story is perceived, not to replace primary research on SEC filings, clinical data or official press releases.

7. 2026 catalyst map: ReSTART, pancreas, Japan and GBM

Putting together the Q3 2025 update, the January PMA and ASCO GI communications, and the shareholder letter, the 2026–early-2027 catalyst map for Alpha Tau looks roughly like this:

The exact dates will move, as always in biotech, but the underlying message is stable: 2026 is not a “dead year” where investors are stuck waiting for a distant, binary event. On the contrary, it is a dense period with multiple layers of clinical and regulatory information arriving across several tumor types.

8. Big picture: what changed since our December note

When we first wrote about Alpha Tau at the end of December, the company looked like a promising, under-followed alpha-radiation platform with decent cash and a pipeline that was still not properly appreciated by the broader market. After January, three things have clearly changed.

First, visibility. The combination of PMA module submission, pancreatic data at a major conference and a structured shareholder letter pulled Alpha Tau onto the radar of more funds and active traders. Visibility does not guarantee success, but it matters for liquidity, access to capital markets and the kind of partners that will seriously consider collaborations.

Second, story structure. Instead of a vague “we are testing Alpha DaRT in many tumors”, the company now presents a clearer staircase: r-cSCC as the lead, head & neck and Japan as important pillars, pancreas and GBM as high-need adjacencies, and further tumor types as optionality. That is the kind of structure that institutional investors can plug into their models.

Third, market expectations. With the stock now trading closer to its 52-week highs and analyst targets that incorporate some degree of success in the lead programs, the bar for future data is higher than it was when DRTS was stuck in the low-single digits. Positive surprises can still re-rate the name further, but disappointing readouts or delays will probably be punished more quickly now that the stock has a larger, more vocal following.

For long-term followers, January’s move is a validation of the idea that Alpha Tau deserved more attention than it was getting in 2025. For newer readers discovering the story because of the recent rally, the key is to go beyond the daily chart and spend time with the primary sources: the official SEC filings, the clinical trial registries and the company’s own technical materials on Alpha DaRT.

This follow-up report is an educational snapshot of where DRTS stands after a very active January 2026. It is not a forecast, and it is not a recommendation to buy, sell or hold the stock. As always, each reader should do their own research, read the full risk factors in the company’s latest Form 20-F and other SEC filings, and consider their own risk tolerance before taking any decision.

Disclaimer (EN): This article is for informational and educational purposes only and does not constitute investment advice, legal advice or a solicitation to buy or sell any security. The data and opinions discussed here are based on public information from SEC filings, official press releases, company presentations and recognized financial data providers available at the time of writing. Numbers and timelines may change as new information is released. Always refer to the original filings on SEC EDGAR, to the company’s investor-relations page and to official regulatory documents before making any investment decision.